LH pretreatment as a novel strategy for poor responders
- PMID: 25197669
- PMCID: PMC4145542
- DOI: 10.1155/2014/926172
LH pretreatment as a novel strategy for poor responders
Abstract
Introduction: Poor response to ovarian stimulation is still a major problem in IVF. The study presents a new stimulation protocol evaluated in a suppopulation of very difficult young poor ovarian responders.
Material and methods: The study consists in two sections. The first includes data from a randomized controlled study involving forty-three young patients with a poor ovarian response in at least two previous cycles (intended as cycle cancellation or with ≤3 collected oocytes). Patients were randomized in two groups: group A (control) received FSH (400 IU/day), while group B received the new stimulation protocol consisting in a sequential association of 150 IU r-LH for 4 days followed by 400 IU r-FSH/after downregulation with daily GnRh agonist. The second includes data from the overall results in 65 patients treated with the new protocol compared to their previous performance with conventional cycles (historical control).
Results: Both in the RCT and in the historical control study, LH pretreatment was able to decrease the cancellation rate, to improve the in vitro performance, and to significantly increase the live birth rates.
Conclusions: LH pretreatment improved oocyte quantity and quality in young repeated poor responders selected in accordance with the Bologna criteria.
Similar articles
-
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.Cochrane Database Syst Rev. 2017 May 24;5(5):CD005070. doi: 10.1002/14651858.CD005070.pub3. Cochrane Database Syst Rev. 2017. PMID: 28537052 Free PMC article. Review.
-
Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.Hum Reprod. 2015 May;30(5):1188-95. doi: 10.1093/humrep/dev038. Epub 2015 Mar 3. Hum Reprod. 2015. PMID: 25740882 Clinical Trial.
-
Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.Hum Reprod. 2015 Oct;30(10):2321-30. doi: 10.1093/humrep/dev198. Epub 2015 Aug 25. Hum Reprod. 2015. PMID: 26307091
-
Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.Hum Reprod. 2017 Nov 1;32(11):2225-2233. doi: 10.1093/humrep/dex296. Hum Reprod. 2017. PMID: 29040589 Clinical Trial.
-
Outlook: who needs LH in ovarian stimulation?Reprod Biomed Online. 2006 May;12(5):599-607. doi: 10.1016/s1472-6483(10)61186-8. Reprod Biomed Online. 2006. PMID: 16790105 Review.
Cited by
-
Subtle perturbations of ovarian steroidogenesis in patients classified as Poseidon Group 3. Which consequences for therapeutic strategy?Front Endocrinol (Lausanne). 2024 Feb 7;15:1231585. doi: 10.3389/fendo.2024.1231585. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38384970 Free PMC article.
-
Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review.Front Endocrinol (Lausanne). 2022 Aug 1;13:907249. doi: 10.3389/fendo.2022.907249. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35979440 Free PMC article. Review.
-
Effect of recombinant LH supplementation timing on clinical pregnancy outcome in long-acting GnRHa downregulated cycles.BMC Pregnancy Childbirth. 2022 Aug 9;22(1):632. doi: 10.1186/s12884-022-04963-x. BMC Pregnancy Childbirth. 2022. PMID: 35945551 Free PMC article.
-
Commentary: Management Strategies for POSEIDON Groups 3 and 4.Front Endocrinol (Lausanne). 2020 Jan 24;10:920. doi: 10.3389/fendo.2019.00920. eCollection 2019. Front Endocrinol (Lausanne). 2020. PMID: 32038485 Free PMC article. No abstract available.
-
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.Cochrane Database Syst Rev. 2017 May 24;5(5):CD005070. doi: 10.1002/14651858.CD005070.pub3. Cochrane Database Syst Rev. 2017. PMID: 28537052 Free PMC article. Review.
References
-
- Surrey ES, Schoolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertility and Sterility. 2000;73(4):667–676. - PubMed
-
- Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Human Reproduction Update. 2003;9(1):61–76. - PubMed
-
- Loutradis D, Vomvolaki E, Drakakis P. Poor responder protocols for in-vitro fertilization: options and results. Current Opinion in Obstetrics and Gynecology. 2008;20(4):374–378. - PubMed
-
- Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertility and Sterility. 2009;91(3):749–766. - PubMed
-
- Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for “poor responders” to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF) Cochrane Database of Systematic Reviews. 2010;(1)CD004379 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
